β1-adrenergic receptor gene polymorphisms and the acute response to atenolol in healthy young Japanese subjects

Journal of Pharmacological Sciences

Volumn 115, Issue 4, 2011, Pages 490-499

  Sasaguri, Toshiyuki ^a   Shiraishi, Fumie ^a   Yoshihara, Tatsuya ^a   Takahashi Yanaga, Fumi ^a   Morimoto, Sachio ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Atenolol; Polymorphism; Randomized double blind trial; blocker

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR; PLACEBO;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CODON; CONTROLLED STUDY; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HEART RATE; HUMAN; HUMAN EXPERIMENT; JAPANESE; MALE; NORMAL HUMAN; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL;

EID: 79955013702     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10332FP     Document Type: Article

References (40)

1. Shin J, Johnson JA. Pharmacogenetics of β-blockers. Pharmacotherapy. 2007;27:874-887.
2. Small KM, McGraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol. 2003;43:381-411. (Pubitemid 37372647)
3. Kirstein SL, Insel PA. Autonomic nervous system pharmacogenomics: a progress report. Pharmacol Rev. 2004;56:31-52. (Pubitemid 38314579)
4. 1-Adrenergic receptor polymorphisms and linkage disequilibrium. Clin Pharmacol Ther. 2002;71:P70.
5. Brodde OE, Bruck H, Leineweber K. Cardiac adrenoceptors: physiological and pathophysiological relevance. J Pharmacol Sci. 2006;100:323-337. (Pubitemid 44609527)
6. Brodde OE. β-1 and β-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses. Pharmacol Ther. 2008;117:1-29.
7. 2- Adrenoceptor polymorphisms and cardiovascular diseases. Br J Pharmacol. 2009;158: 61-69.
8. 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem. 2002;277:30429-30435.
9. 1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol. 2002;39: 155-160.
10. Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human β1-adrenergic receptor. J Biol Chem. 1999;274:12670-12674. (Pubitemid 29215505)
11. 2-adrenergic receptor signaling. J Biol Chem. 2003;278:10784-10789.
12. 1-adrenoceptors. Br J Pharmacol. 2004;142:51-56.
13. 1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to β-blockade. Clin Pharmacol Ther. 2003;73:366-371.
14. 1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther. 2003;74:372-379.
15. 1-Adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther. 2003;74: 44-52.
16. Brown HC, Carruthers SG, Johnston GD, Kelly JG, McAinsh J, McDevitt DG, et al. Clinical pharmacologic observations on atenolol, a β-adrenoceptor blocker. Clin Pharmacol Ther. 1976; 20:524-534.
17. Shioji K, Kokubo Y, Mannami T, Inamoto N, Morisaki H, Mino Y, et al. Association between hypertension and the α-adducin, α1- adrenoreceptor, and G-protein β3 subunit genes in the Japanese population; the Suita study. Hypertens Res. 2004;27:31-37.
18. Matsunaga T, Yasuda K, Adachi T, Gu N, Yamamura T, Moritani T, et al. Association of β-adrenoceptor polymorphisms with cardiac autonomic modulation in Japanese males. Am Heart J. 2007;154:759-766.
19. 1 adrenergic receptor gene and massive obesity in Japanese. Diabetes Res Clin Pract. 2008;80: 213-217.
20. 1-adrenoceptor genetic variants and ethnicity independently affect response to β-blockade. Pharmacogenet Genomics. 2008;18:895-902.
21. 1-adrenoceptor does not influence blood pressure or heart rate response to β-blockade in hypertensive subjects. Clin Sci. 2000;99:33-38.
22. 1-adrenergic receptor blockade in patients with essential hypertension. Clin Cardiol. 2004;27:347-350.
23. 2-adrenergic receptor and response to four classes of antihypertensive treatment. Pharmacogenet Genomics. 2010;20:342-345.
24. Feldman DS, Carnes CA, Abraham WT, Bristow MR. Mechanisms of disease: β-adrenergic receptors-alterations in signal transduction and pharmacogenomics in heart failure. Nat Rev Cardiol. 2005;2:475-483.
25. 1-adrenergic receptor polymorphisms in heart failure. Heart Failure Clin. 2010;6:27-33.
26. 1-adrenergic receptor polymor phisms confer differential function and predisposition to heart failure. Nat Med. 2003;9:1300-1305.
27. 1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006; 103:11288-11293.
28. Terra SG, Pauly DF, Lee CR, Patterson JH, Adams KF, Schofield RS, et al. β-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther. 2005;77:127-137.
29. 1-Adrenergic receptor polymorphisms and left ventricular remodeling changes in response to β-blocker therapy. Pharmacogenet Genomics. 2005;15:227-234.
30. 1-adrenergic receptor is associated with effective β-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther. 2005;78:221-231.
31. 1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail. 2003;5: 463-468.
32. 2 adrenergic receptor gene polymorphisms and the response to β-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics. 2005;15:137-142.
33. 2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol. 2006;70:1575-1584.
34. 1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J Clin Invest. 2007;117:229-235.
35. 1Arg389 and the risk for heart failure in the Japanese population. Br J Clin Pharmacol. 2005;60:414-417.
36. 2c-adrenergic receptors and the risk of congestive heart failure. N Engl J Med. 2002; 347:1135-1142.
37. 2c- adrenergic receptors and the influence on left ventricular ejection fraction response to β-blocker therapy in heart failure. Pharmacogenet Genomics. 2007;17:277-282.
38. 2c-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the β-blocker bucindolol in chronic heart failure. Circ Heart Fail. 2010;3:21-28.
39. 2-Adernoceptor gene polymorphisms. Pharmacogenet Genomics. 2005;15:267-275.
40. 1-adrenergic blockade in humans. Pharmacogenomics. 2009;10:1581-1587.